Cx3cr1-binding polypeptides

A nucleic acid molecule encoding a polypeptide comprising an anti-CX3CR1 (anti-CX3 chemokine receptor 1) immunoglobulin single variable domain, wherein said polypeptide comprises a CDR1, CDR2 and CDR3 having the amino acid sequences set forth in:

• SEQ ID No:
• 141, 162 and 186, respectively;
• or
• SEQ ID No:
• 141, 163 and 187, respectively;
• or
• SEQ ID No:
• 141, 164 and 186, respectively;
• or
• SEQ ID No:
• 141, 166 and 186, respectively;
• or
• SEQ ID No:
• 141, 167 and 186, respectively;
• or
• SEQ ID No:
• 141, 167 and 189, respectively;
• or
• SEQ ID No:
• 141, 168 and 186, respectively;
• or
• SEQ ID No:
• 141, 168 and 187, respectively;
• or
• SEQ ID No:
• 141, 169 and 190, respectively;
• or
• SEQ ID No:
• 141, 170 and 186, respectively;
• or
• SEQ ID No:
• 141, 171 and 186, respectively;
• or
• SEQ ID No:
• 141, 174 and 186, respectively;
• or
• SEQ ID No:
• 141, 175 and 187, respectively;
• or
• SEQ ID No:
• 142, 165 and 188, respectively;
• or
• SEQ ID No:
• 142, 173 and 188, respectively;
• or
• SEQ ID No:
• 143, 164 and 186, respectively;
• or
• SEQ ID No:
• 144, 172 and 187, respectively;
• or
• SEQ ID No:
• 145, 172 and 187, respectively;
• or
• SEQ ID No:
• 141, 214 and 186, respectively;
• or
• SEQ ID No:
• 141, 215 and 186, respectively;
• or
• SEQ ID No:
• 141, 216 and 186, respectively;
• or
• SEQ ID No:
• 141, 217 and 186, respectively;
• or
• SEQ ID No:
• 141, 218 and 186, respectively;
• or
• SEQ ID No:
• 141, 219 and 186, respectively;
• or
• SEQ ID No:
• 141, 220 and 186, respectively;
• or
• SEQ ID No:
• 213, 221 and 186, respectively;
• or
• SEQ ID No:
• 213, 214 and 186, respectively.

A method of manufacturing a polypeptide comprising an anti-CX3CR1 (anti-CX3 chemokine receptor 1) immunoglobulin single variable domain, wherein said polypeptide comprises a CDR1, CDR2 and CDR3 having the amino acid sequences set forth in:

• SEQ ID No:
• 141, 162 and 186, respectively;
• or
• SEQ ID No:
• 141, 163 and 187, respectively;
• or
• SEQ ID No:
• 141, 164 and 186, respectively;
• or
• SEQ ID No:
• 141, 166 and 186, respectively;
• or
• SEQ ID No:
• 141, 167 and 186, respectively;
• or
• SEQ ID No:
• 141, 167 and 189, respectively;
• or
• SEQ ID No:
• 141, 168 and 186, respectively;
• or
• SEQ ID No:
• 141, 168 and 187, respectively;
• or
• SEQ ID No:
• 141, 169 and 190, respectively;
• or
• SEQ ID No:
• 141, 170 and 186, respectively;
• or
• SEQ ID No:
• 141, 171 and 186, respectively;
• or
• SEQ ID No:
• 141, 174 and 186, respectively;
• or
• SEQ ID No:
• 141, 175 and 187, respectively;
• or
• SEQ ID No:
• 142, 165 and 188, respectively;
• or
• SEQ ID No:
• 142, 173 and 188, respectively;
• or
• SEQ ID No:
• 143, 164 and 186, respectively;
• or
• SEQ ID No:
• 144, 172 and 187, respectively;
• or
• SEQ ID No:
• 145, 172 and 187, respectively;
• or
• SEQ ID No:
• 141, 214 and 186, respectively;
• or
• SEQ ID No:
• 141, 215 and 186, respectively;
• or
• SEQ ID No:
• 141, 216 and 186, respectively;
• or
• SEQ ID No:
• 141, 217 and 186, respectively;
• or
• SEQ ID No:
• 141, 218 and 186, respectively;
• or
• SEQ ID No:
• 141, 219 and 186, respectively;
• or
• SEQ ID No:
• 141, 220 and 186, respectively;
• or
• SEQ ID No:
• 213, 221 and 186, respectively;
• or
• SEQ ID No:
• 213, 214 and 186, respectively.
• comprising the steps of
• culturing a host cell under conditions that allow expression of said polypeptide,
• wherein said host cell is carrying an expression vector comprising a nucleic acid molecule, said nucleic acid molecule comprising a region encoding said polypeptide and wherein said host cell is a prokaryotic or a eukaryotic cell.